Synlogic, Inc. (SYBX): Price and Financial Metrics


Synlogic, Inc. (SYBX)

Today's Latest Price: $2.45 USD

0.01 (0.41%)

Updated May 28 8:00pm

Add SYBX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SYBX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for SYBX is 0.01 -- better than merely 9.36% of US stocks.
  • With a price/sales ratio of 40.35, Synlogic Inc has a higher such ratio than 95.97% of stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SYBX comes in at -70.8% -- higher than that of just 6.63% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Synlogic Inc, a group of peers worth examining would be EVGN, CDTX, CLDX, KALV, and PIRS.
  • SYBX's SEC filings can be seen here. And to visit Synlogic Inc's official web site, go to www.synlogictx.com.
SYBX Daily Price Range
SYBX 52-Week Price Range

SYBX Stock Price Chart More Charts


SYBX Price/Volume Stats

Current price $2.45 52-week high $10.01
Prev. close $2.44 52-week low $1.35
Day low $2.30 Volume 833,900
Day high $2.55 Avg. volume 403,436
50-day MA $2.05 Dividend yield N/A
200-day MA $2.37 Market Cap 80.46M

Synlogic, Inc. (SYBX) Company Bio


Synlogic, Inc., a biopharmaceutical company, offers synthetic biotics that perform specific metabolic functions from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. It provides SYNB1010 for urea cycle disorder, a synthetic biotic that is designed to remove excess ammonia from the blood; and SYNB2010 for phenylketonuria, a synthetic biotic that is designed to remove excess phenylalanine from the blood. The company was founded in 2013 and is based in Cambridge, Massachusetts.


SYBX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

SYBX Latest Social Stream


Loading social stream, please wait...

View Full SYBX Social Stream

Latest SYBX News From Around the Web

Below are the latest news stories about Synlogic Inc that investors may wish to consider to help them evaluate SYBX as an investment opportunity.

Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines called Synthetic Bioticâ„¢ medicines, today provided an update on its business operations and expected clinical activities as a result of the COVID-19 pandemic. In the interest of patient safety, as well as aligning with the needs of clinical sites, Synlogic expects that enrollment of subjects into its planned Phase 2 clinical study of SYNB1618 in patients with phenylketonuria (PKU) will be delayed and expects slower enrollment of new subjects into its ongoing Phase 1 clinical trial of SYNB1891.

Yahoo | March 30, 2020

Synlogic, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know

Shareholders in Synlogic, Inc. (NASDAQ:SYBX) had a terrible week, as shares crashed 24% to US$1.59 in the week since...

Yahoo | March 15, 2020

Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial results for the fourth quarter and full year ended December 31, 2019.

Yahoo | March 12, 2020

Synlogic, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Synlogic, Inc. (NASDAQ:SYBX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 5:00 PM Eastern ...

Yahoo | March 12, 2020

Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit

Synlogic (Nasdaq: SYBX) announced today that Richard Riese, M.D., Ph.D., Synlogic's chief medical officer, will present at the Chardan Microbiome Medicines Summit at Noon ET on Monday, March 16th, 2020.

Yahoo | March 11, 2020

Read More 'SYBX' Stories Here

SYBX Price Returns

1-mo 15.02%
3-mo 18.93%
6-mo 14.49%
1-year -70.05%
3-year -75.86%
5-year N/A
YTD -5.04%
2019 -63.20%
2018 -27.73%
2017 -23.02%
2016 -71.20%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9 seconds.